Pharmaxis Commences Final Cohort Dosing in Bone Marrow Cancer Phase 1c Trial
4th
Aug 21
Release Date: 04/08/2021 8:53am
- Second Dose Level in PXS-5505 Myelofibrosis Study Showing Dose Related Increase in Blood Drug Levels and Good Safety Profile in Patients
- Safety Committee Clear Progression to Final Dose
Categories: News and Media